Signaturefd, LLC Arcutis Biotherapeutics, Inc. Transaction History

Signaturefd, LLC

$4.72 Billion
Q1 2024

A detailed history of Signaturefd, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 3,519 shares of ARQT stock, worth $32,726. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,519

Holding current value

$32,726

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$3.25 - $11.77 $11,436 - $41,418	3,519 New	3,519 $34,000
Q3 2023 Nov 03, 2023	SELL	$5.31 - $10.98 $116 - $241	-22 Reduced 5.98%	346 $1,000
Q2 2023 Aug 01, 2023	BUY	$7.51 - $15.0 $1,877 - $3,750	250 Added 211.86%	368 $3,000
Q1 2023 Apr 28, 2023	SELL	$10.23 - $17.14 $1,780 - $2,982	-174 Reduced 59.59%	118 $1,000
Q4 2022 Jan 27, 2023	SELL	$13.96 - $20.4 $614 - $897	-44 Reduced 13.1%	292 $4,000

Q3 2022 Nov 08, 2022	SELL	$17.85 - $26.95 $874 - $1,320	-49 Reduced 12.73%	336 $6,000
Q2 2022 Aug 10, 2022	BUY	$16.33 - $22.2 $1,518 - $2,064	93 Added 31.85%	385 $8,000
Q1 2022 May 02, 2022	BUY	$14.38 - $22.79 $4,055 - $6,426	282 Added 2820.0%	292 $6,000
Q4 2021 Jan 25, 2022	SELL	$14.98 - $25.5 $8,763 - $14,917	-585 Reduced 98.32%	10 $0
Q3 2021 Oct 28, 2021	BUY	$19.28 - $27.1 $11,471 - $16,124	595 New	595 $14,000

Others Institutions Holding ARQT

# of Institutions

172

Shares Held

126M

Call Options Held

498K

Put Options Held

1.64M

Jennison Associates LLC

12.2M
Shares

$113 Million
0.08% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.79M
Shares

$81.7 Million
4.57% of portfolio
State Street Corp Boston, MA

8.78M
Shares

$81.7 Million
0.0% of portfolio
Suvretta Capital Management, LLC New York, NY

7.88M
Shares

$73.3 Million
3.34% of portfolio
Rubric Capital Management LP New York, NY

7.51M
Shares

$69.8 Million
2.54% of portfolio

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account